- Alpine Immune Sciences Inc ALPN has entered into a clinical trial collaboration and supply agreement with Merck & Co Inc MRK.
- This collaboration will evaluate the safety and efficacy of Alpine's ALPN-202 in combination with Merck's Keytruda (pembrolizumab) in patients with advanced malignancies.
- Dubbed as NEON-2, the trial is currently enrolling.
- Price Action: ALPN shares are down 1.93% at $8.92 during the market session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
